The overall goal of this research program is to establish a rational foundation for the combination chemotherapy of cancer. The approach is based on the concept of employing combinations of metabolites and antimetabolites to modulate biochemical pathways with the view of achieving maximal cancer cell damage while simultaneously protecting moral host cells from drug toxicity. Much of the basic information upon which a rational for a particular drug combination is based comes from in vitro studies of others. However, since the ultimate utility of a drug combination depends upon the selective achievement of the appropriate modulation(s) of biochemical pathways in vivo, studies in Research Project 2 will be designed to determine the biochemical effect of a given modulating agent on the final activity of the primary effector agent in vivo. Thus, therapeutic results from a particular drug manipulation, obtained as expected on the basis of the biochemical information that prompted that manipulation, will be confirmed on a biochemical level to insure that the biological results are related to the predicted biochemical changes. Unexpected therapeutic results will be explored at the biochemical level to provide new information that will be utilized to alter the drug combination (or schedule) so as to achieve the desired therapeutic advance. (It must be stressed that the NMR and biochemical studies will be performed with tissues obtained from mice undergoing the in vivo therapeutic regimen in question). Of great importance, these in vivo biochemical, pharmacological, and NMR studies will provide guidelines for comparative pharmacological, and biochemical and NMR studies in the clinic (Research Project 3, Clinical Studies) which will be used to adjust promising therapeutic drug regimens for translation from the animal tumor model to cancer patients. The combined in vivo biological and biochemical findings, Project 1 and 2, lead to guidelines for specific clinical trials; feedback from Project 3, Clinical Studies, may suggest new experimental studies and refinements.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA025842-10
Application #
3812209
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1990
Total Cost
Indirect Cost
Name
St. Vincent Catholic Medical Center Nursing
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
11432
Martin, D S; Spriggs, D; Koutcher, J A (2001) A concomitant ATP-depleting strategy markedly enhances anticancer agent activity. Apoptosis 6:125-31
Koutcher, J A; Alfieri, A A; Tsai, J C et al. (1997) Evaluation of chemotherapy and radiation enhancement and 31P NMR spectral changes induced by biochemical modulation. Cancer Invest 15:111-20
Koutcher, J A; Alfieri, A A; Thaler, H et al. (1997) Radiation enhancement by biochemical modulation and 5-fluorouracil. Int J Radiat Oncol Biol Phys 39:1145-52
Martin, D S; Stolfi, R L; Colofiore, J R (1997) Perspective: the chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis. Cancer Invest 15:372-81
Street, J C; Alfieri, A A; Koutcher, J A (1997) Quantitation of metabolic and radiobiological effects of 6-aminonicotinamide in RIF-1 tumor cells in vitro. Cancer Res 57:3956-62
Kelsen, D P; Martin, D; O'Neil, J et al. (1997) Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J Clin Oncol 15:1511-7
Street, J C; Koutcher, J A (1997) Effect of radiotherapy and chemotherapy on composition of tumor membrane phospholipids. Lipids 32:45-9
Nord, L D; Stolfi, R L; Alfieri, A A et al. (1997) Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion. Cancer Chemother Pharmacol 40:376-84
Martin, D S; Schwartz, G K (1997) Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade. Oncol Res 9:1-5
Stolfi, R L; Colofiore, J R; Nord, L D et al. (1996) Enhanced antitumor activity of an adriamycin + 5-fluorouracil combination when preceded by biochemical modulation. Anticancer Drugs 7:100-4

Showing the most recent 10 out of 48 publications